Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Given "Buy" Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Actinium Pharmaceuticals (NYSEAMERICAN:ATNM - Free Report) in a report published on Monday, Benzinga reports. They currently have a $50.00 price target on the biotechnology company's stock.

A number of other analysts also recently weighed in on the company. Cantor Fitzgerald restated an overweight rating and issued a $21.00 price target on shares of Actinium Pharmaceuticals in a research note on Monday, April 1st. Maxim Group upped their price target on shares of Actinium Pharmaceuticals from $20.00 to $30.00 and gave the stock a buy rating in a research note on Tuesday, March 19th. Finally, StockNews.com cut shares of Actinium Pharmaceuticals from a hold rating to a sell rating in a research note on Tuesday, March 19th. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. According to MarketBeat.com, Actinium Pharmaceuticals presently has an average rating of Moderate Buy and a consensus target price of $25.72.

Actinium Pharmaceuticals Price Performance

ATNM stock traded up $0.56 on Monday, hitting $7.43. The company's stock had a trading volume of 244,842 shares, compared to its average volume of 322,240. The company has a market cap of $218.44 million, a price-to-earnings ratio of -4.06 and a beta of 0.01. Actinium Pharmaceuticals has a 1 year low of $4.00 and a 1 year high of $9.86.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM - Get Free Report) last issued its quarterly earnings results on Friday, March 29th. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.21. The company had revenue of $0.08 million during the quarter. As a group, analysts anticipate that Actinium Pharmaceuticals will post -1.87 earnings per share for the current year.

Hedge Funds Weigh In On Actinium Pharmaceuticals

Several institutional investors have recently made changes to their positions in ATNM. Sanders Morris Harris LLC bought a new stake in Actinium Pharmaceuticals in the first quarter worth about $78,000. Creative Financial Designs Inc. ADV lifted its stake in Actinium Pharmaceuticals by 19.1% during the fourth quarter. Creative Financial Designs Inc. ADV now owns 19,800 shares of the biotechnology company's stock valued at $101,000 after purchasing an additional 3,175 shares during the last quarter. Finally, Brandywine Global Investment Management LLC acquired a new stake in Actinium Pharmaceuticals during the third quarter valued at approximately $1,033,000. 27.50% of the stock is owned by institutional investors.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.